SABS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.208

-83.06%

-0.190

-66.07%

-0.197

-81.96%

Estimates Revision

The market is revising No Change the revenue expectations for SAB Biotherapeutics, Inc. (SABS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 60.70%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-109.08%

In Past 3 Month

Stock Price

Go Up

+60.70%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast SABS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SABS is 8.00 USD with a low forecast of 7.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

7.00

Averages

8.00

High

9.00

Current: 0.000

Low

7.00

Averages

8.00

High

9.00

UBS

Michael Yee

Buy

initiated

2026-01-07

New

Reason

UBS

Michael Yee

Price Target

2026-01-07

New

initiated

Buy

Reason

UBS analyst Michael Yee initiated coverage of SAB Biotherapeutics with a Buy rating and $7 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.

Guggenheim

NULL -> Buy

initiated

$15

2025-12-19

Reason

Guggenheim

Price Target

$15

2025-12-19

initiated

NULL -> Buy

Reason

Guggenheim initiated coverage of SAB Biotherapeutics with a Buy rating and $15 price target. The company's lead asset, SAB-142, is in pivotal development for Stage 3 Type 1 Diabetes, where no disease-modifying therapy is currently approved, the analyst tells investors. The firm expects positive pivotal SafeGUARD data in T1D in the second half of 2027 and estimates about $2B in peak global sales for SAB-142 in Stage 3 T1D if approved, the analyst added.

Leerink

Outperform

initiated

2025-09-17

Reason

Leerink

Price Target

2025-09-17

initiated

Outperform

Reason

Leerink initiated coverage of SAB Biotherapeutics with an Outperform rating and $7 price target. SAB is a clinical-stage biotech focused on the development of lead asset SAB-142 - a first-in-class, human, multi-target anti-thymocyte globulin aimed at preventing or delaying progression of Type 1 Diabetes. The firm views SAB-142's mechanism as partially derisked in T1D based on multiple clinical studies evaluating rabbit ATG, which has shown an ability to preserve an important biomarker of beta cell function and delay T1D progression. Leerink sees ample commercial opportunity for SAB-142 based on MEDACorp KOL feedback highlighting the significant unmet need among newly diagnosed T1D patients and lack of approved therapies for delaying or preventing progression of the disease.

Chardan

Buy

downgrade

$20 -> $12

2025-08-08

Reason

Chardan

Price Target

$20 -> $12

2025-08-08

downgrade

Buy

Reason

Chardan lowered the firm's price target on SAB Biotherapeutics to $12 from $20 and keeps a Buy rating on the shares after the company reported Q2 results. A recent financing will fund the potentially pivotal Phase IIb SAFEGUARD trial of SAB-142 in type I diabetes, notes the analyst, who cites dilution from the fundraising for the company's lowered target.

H.C. Wainwright

initiated

$10

2025-05-14

Reason

H.C. Wainwright

Price Target

$10

2025-05-14

initiated

Reason

H.C. Wainwright assumed coverage of SAB Biotherapeutics with a Buy rating and $10 price target. Following a positive topline data readout in healthy volunteers that showcased sustained immunomodulation and a clean safety profile, SAB's human anti-thymocyte immunoglobulin, SAB-142, is positioning itself as a potential new immunotherapy to prevent and control the progression of type 1 diabetes, the analyst tells investors in a research note.

HC Wainwright & Co.

Edward White

Strong Buy

Reiterates

2025-04-01

Reason

HC Wainwright & Co.

Edward White

Price Target

2025-04-01

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for SAB Biotherapeutics Inc (SABS.O) is -4.73, compared to its 5-year average forward P/E of -9.28. For a more detailed relative valuation and DCF analysis to assess SAB Biotherapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.28

Current PE

-4.73

Overvalued PE

5.92

Undervalued PE

-24.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

45.99

Current PS

0.00

Overvalued PS

138.94

Undervalued PS

-46.95

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 10058566.67% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SABS News & Events

Events Timeline

No data

News

9.0

2025-12-17Globenewswire

SAB Biotherapeutics Advances SAB-142 Clinical Trial for Stage 3 Diabetes Treatment Following Positive Phase 1 Results

9.0

2025-12-17Newsfilter

SAB Biotherapeutics Confirms SAB-142 Safety, Advances to Phase 2b Clinical Trial

9.5

2025-11-13Newsfilter

SAB BIO Announces Financial Results for Third Quarter and Key Business Updates

People Also Watch

Frequently Asked Questions

What is SAB Biotherapeutics Inc (SABS) stock price today?

The current price of SABS is 3.68 USD — it has decreased -4.66 % in the last trading day.

What is SAB Biotherapeutics Inc (SABS)'s business?

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.

What is the price predicton of SABS Stock?

What is SAB Biotherapeutics Inc (SABS)'s revenue for the last quarter?

SAB Biotherapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is SAB Biotherapeutics Inc (SABS)'s earnings per share (EPS) for the last quarter?

SAB Biotherapeutics Inc. EPS for the last quarter amounts to -0.21 USD, decreased -81.25 % YoY.

What changes have occurred in the market's expectations for SAB Biotherapeutics Inc (SABS)'s fundamentals?

How many employees does SAB Biotherapeutics Inc (SABS). have?

SAB Biotherapeutics Inc (SABS) has 63 emplpoyees as of January 10 2026.

What is SAB Biotherapeutics Inc (SABS) market cap?

Today SABS has the market capitalization of 175.19M USD.